SUGP:NASDAQSU Group Holdings Limited Analysis
Data as of 2026-05-03 - not real-time
$4.33
Latest Price
8/10Risk
Risk Level: High
Executive Summary
The stock is trading at $4.33, well below its 200‑day SMA of $6.10, indicating a significant discount to its long‑term trend. However, the 20‑day SMA ($4.70) sits above the current price, confirming short‑term weakness. The 14‑day RSI at 32.6 points to oversold conditions, suggesting potential for a rebound. MACD remains in bearish territory, with the line (-0.19) below the signal (-0.16) and a negative histogram, reinforcing downside momentum. Volume is increasing, yet price remains trapped between support at $4.17 and resistance at $5.11, limiting upside. The stock’s beta of 2.07 and 30‑day volatility of 44.5% signal extreme price swings, amplifying risk.
Fundamentally, the company reports negative operating margin (-17.8%) and a net loss per share of -$1.71, with a trailing EPS of -1.71, highlighting earnings weakness. Yet its price‑to‑book ratio of 0.58 and price‑to‑sales of 0.05 are far below industry averages, implying a deep value discount. The balance sheet shows modest cash of $25.3 M against debt of $5.5 M, resulting in a high debt‑to‑equity of 6.4, which could strain liquidity. Free cash flow is negative ($‑13.3 M) and operating cash flow also negative, raising concerns about cash generation. The maximum historical drawdown of -73.9% and a market cap of only $10.2 M underscore the company’s fragility. Coupled with an “Extreme Greed” market sentiment, the technical and fundamental picture points to a high‑risk, value‑oriented play.
Fundamentally, the company reports negative operating margin (-17.8%) and a net loss per share of -$1.71, with a trailing EPS of -1.71, highlighting earnings weakness. Yet its price‑to‑book ratio of 0.58 and price‑to‑sales of 0.05 are far below industry averages, implying a deep value discount. The balance sheet shows modest cash of $25.3 M against debt of $5.5 M, resulting in a high debt‑to‑equity of 6.4, which could strain liquidity. Free cash flow is negative ($‑13.3 M) and operating cash flow also negative, raising concerns about cash generation. The maximum historical drawdown of -73.9% and a market cap of only $10.2 M underscore the company’s fragility. Coupled with an “Extreme Greed” market sentiment, the technical and fundamental picture points to a high‑risk, value‑oriented play.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 8/10
Key Factors
- Bearish MACD histogram
- RSI below 40 indicating oversold but momentum still negative
- Price below short‑term SMA and approaching support level
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Deep valuation discount (low P/B and P/S)
- Continued negative earnings and cash flow
- High beta and volatility may delay recovery
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Potential upside if turnaround improves margins
- Strong asset base relative to market cap
- Persistent regulatory and liquidity challenges
Key Metrics & Analysis
Financial Health
Revenue Growth-6.50%
Profit Margin-9.61%
ROE-20.11%
ROA-7.94%
Debt/Equity6.40
P/B Ratio0.6
Op. Cash Flow$-15456974
Free Cash Flow$-13327510
Industry P/E31.2
Technical Analysis
TrendBearish
RSI32.6
Support$4.17
Resistance$5.11
MA 20$4.70
MA 50$4.96
MA 200$6.10
MACDBearish
VolumeIncreasing
Fear & Greed Index91.09
Valuation
GradeUndervalued
TypeValue
Risk Assessment
Beta2.07
Volatility44.54%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.